The power of inclusion - Bristol Myers Squibb
The power of inclusion
At Bristol Myers Squibb, valuing diverse perspectives is deliberate, and strengthening a culture of inclusion is intentional. Our global People & Business Resource Groups (PBRGs) are aligned to a transformational, single-leader business model that has helped to inform key business decisions and enhance our global patient focus.
Our PBRGs are instrumental in driving the company’s Global Diversity & Inclusion strategy, which is committed to advancing a culture of inclusion. That culture relies on the diversity of people with unique experiences and backgrounds to deliver on our patient-focused mission and business objectives. With leadership from the PBRGs, Bristol Myers Squibb has implemented programs in support of patients and our people around the world. These programs include:
- The Bristol Myers Squibb Network of Women partnered with human resources leadership to revise the company parental leave policy in the US. It now provides for 12 weeks of paid and 16 weeks of unpaid leave, regardless of parental gender.
- The Veterans Community Network partnered with human resources to introduce a new Military Leave Policy offering full pay for 24 months for full- and part-time US and Puerto Rico employees engaged in uniformed services. Enhanced Employee Assistance Program services and two weeks’ paid leave for a readjustment period between return from deployment and reporting back to work are also available.
- The Pan Asian Network partnered with our commercial organization to develop a cultural agility development program for sales team members to improve cultural competence, build trust, and engage authentically with Asian American healthcare professionals.
- Determined to help our company address the social unrest in the US, all eight PBRGs identified social justice organizations fighting disparities and discrimination as part of our employee giving program’s 2-to-1 match.
Transforming patients' lives through science
The touch that transforms
2021 Annual Report
Visit bms.com to see how we're bringing a human touch to everything we do.
© 2022 Bristol-Myers Squibb Company
The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.